80866-81-5

Basic information

• Product Name: 1-(4-CHLOROPHENYL)-1-CYCLOPROPANEMETHANOL
• Synonyms: 1-(4-CHLOROPHENYL)-1-CYCLOPROPANEMETHANOL;[1-(4-CHLORO-PHENYL)-CYCLOPROPYL]-METHANOL;1-(p-chlorophenyl)cyclopropanemethanol;1-(4-Chlorophenyl)cyclopropanemethanol;1-(4-Chlorophenyl)-1-cyclopropanemethanol,98%
• CAS NO: 80866-81-5
• Molecular Formula: C₁₀H₁₁ClO
• Molecular Weight: 182.65
• EINECS: 279-585-1
• Mol File: 80866-81-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 50-54 °C
• Boiling Point: 260.78°C (rough estimate)
• Flash Point: 122.4°C
• Appearance: /
• Density: 1.0929 (rough estimate)
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.5169 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-CHLOROPHENYL)-1-CYCLOPROPANEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROPHENYL)-1-CYCLOPROPANEMETHANOL(80866-81-5)
• EPA Substance Registry System: 1-(4-CHLOROPHENYL)-1-CYCLOPROPANEMETHANOL(80866-81-5)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 80866-81-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H11ClO/c11-9-3-1-8(2-4-9)10(7-12)5-6-10/h1-4,12H,5-7H2

Upstream product

• 117252-05-8 methyl 1-(4-chlorophenyl)cyclopropane-1-carboxylate 
• 64399-27-5 1-(4-chlorophenyl)-1-cyclopropanecarbonitrile 
• 140-53-4 p-chlorobenzyl cyanide 
• 72934-37-3 3-(4-chlorophenyl)-1-cyclopropanecarboxylic acid 

Downstream Products

• 88934-59-2 1-(((1-(4-ethoxyphenyl)cyclopropyl)methoxy)methyl)-3-phenoxybenzene 
• 1043500-05-5 1-chloro-4-(1-iodomethyl-cyclopropyl)benzene 
• 100845-90-7 1-carboxaldehyde-1-(p-chlorophenyl)-cyclopropane 
• 198976-38-4 3-(R-3-piperidyloxy)-4-(1-(4-chlorophenyl)cyclopropylmethoxy)-1,2,5-thiadiazole 

Relevant articles and documents

Synthesis and stereostructure-activity relationship of novel pyrethroids possessing two asymmetric centers on a cyclopropane ring

2-Methylcyclopropane pyrethroid insecticides bearing chiral cyanohydrin esters or chiral ethers and two asymmetric centers on the cyclopropane ring, were synthesized. These compounds were designed using a “reverse connection approach” between the isopropyl group in Fenvalerate, and between two dimethyl groups in an Etofenprox analogue (the methyl, ethyl form), respectively. These syntheses were achieved by accessible ring opening reactions of commercially available (±)-, (R)-, and (S)-propylene oxides using 4-chlorobenzyl cyanide anion as the crucial step, giving good overall yield of the product with >98% ee. The insecticidal activity against the common mosquito (Culex pipiens pallens) was assessed for pairs of achiral diastereomeric (1R*,2S*)-, (1R*,2R*)-cyanohydrin esters, and (1R*,2S*)-, (1R*,2R*)-ethers; only the (1R*,2R*)-ether was significantly effective. For the enantiomeric (1S,2S)-ether and (1R,2R)-ether, the activity was clearly centered on the (1R,2R)-ether. The present stereostructure?activity relationship revealed that (i) cyanohydrin esters derived from fenvalerate were unexpectedly inactive, whereas ethers derived from etofenprox were active, and (ii) apparent chiral discrimination between the (1S,2S)-ether and the (1R,2R)-ether was observed. During the present synthetic study, we performed alternative convergent syntheses of Etofenprox and novel 4-EtO-type (1S,2S)- and (1R,2R)-pyrethroids from the corresponding parent 4-Cl-type pyrethroids, by utilizing a recently-developed hydroxylation cross-coupling reaction.

C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS

The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.

Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.